logo
Ernest Drucker, Public-Health Advocate for the Scorned, Dies at 84

Ernest Drucker, Public-Health Advocate for the Scorned, Dies at 84

New York Times05-02-2025
Ernest Drucker, a pioneering public-health researcher who approached drug addiction with compassion, invigorated needle-exchange programs to stem the AIDS epidemic and diagnosed the destructive impact of what he called a 'plague' of mass incarceration, died on Jan. 26 at his home in Manhattan. He was 84.
The cause was complications of dementia, his son, Jesse Drucker, said.
For more than three decades, Dr. Drucker, primed with epidemiological evidence, waged cutting edge campaigns to improve the lot of prison inmates; the homeless; patients with tuberculosis; workers exposed to asbestos; and HIV-infected drug users and their families, who had been ravaged by the repercussions of AIDS. He was an early and vocal proponent of rethinking the country's approach to illicit drugs, advocating 'harm reduction' — a strategy that prioritizes reducing negative consequences over criminal prosecution.
A clinical psychologist by training, he was professor emeritus of family and social medicine at Montefiore Medical Center/Albert Einstein College of Medicine in the Bronx and had been a senior research associate and scholar in residence at John Jay College of Criminal Justice of the City University of New York in Manhattan, where he biked to work from the Upper West Side.
Dr. Helene Gayle, an epidemiologist and a former president of Spelman College in Atlanta, described Dr. Drucker this way in an email to his son: 'Unapologetic about taking on issues that others wouldn't touch. Unapologetic about the humanity in all including those who had suffered the most injustice.'
Having run a drug rehabilitation program in the Bronx, Dr. Drucker knew firsthand the destructive capabilities of addictive drugs. But the criminal prosecution of addicts, he argued, only compounded the problem, forcing addicts underground, where dangerous practices like sharing needles resulted in the spread of H.I.V., and saddling them with criminal records that could make them unemployable.
'Our demonization of heroin has transformed otherwise benign and controllable patterns of its use into a lethal gamble and has raised the threshold for seeking help when problems do arise,' he wrote in a letter to The New York Times in 1995. 'Other countries are adopting 'harm reduction' strategies that (without legalizing drugs) acknowledge their widespread use and employ methods (such as needle exchange) to make even injectable use safer.'
He added that 'our stubborn failure to acknowledge the enduring appeal of drugs, and learn how to control (rather than prohibit) their use' had tragic consequences.
Instead, he contended in his book 'A Plague of Prisons: The Epidemiology of Mass Incarceration in America' (2011), that for the 90 percent of drug crimes that are nonviolent 'criminalization can be replaced with a public health and therapeutic model.'
Dr. Drucker established some of the world's first syringe exchange programs and in 1991, after he testified in favor of them, four members of the AIDS Coalition to Unleash Power, known as Act Up, were acquitted in Jersey City, N.J., of charges related to running a needle exchange program to prevent the spread of AIDS.
He warned that the AIDS epidemic was not only afflicting gay men but was also increasingly devastating poor, nonwhite families. He said that heterosexual relations in certain Bronx neighborhoods had become a form of 'sexual Russian roulette' that was orphaning children.
'No one, by a long shot, spun out more novel ideas for research, policy and advocacy, many of which resulted in influential publications, new organizations and changes in policy on all aspects of harm reduction as well as drug treatment, public health and criminal justice reform,' Ethan A. Nadelmann, the founder of the Drug Policy Alliance, which has opposed the war on drugs, said in an email.
Dr. Drucker was a founder and chairman of Doctors of the World/USA from 1993 to 1997, was the founding editor in chief of Harm Reduction Journal, and a founder of the International Harm Reduction Association.
In his eulogy, Professor David Michaels of George Washington University's Milken Institute School of Public Health and a former administrator of the federal Occupational Safety and Health Administration, said Dr. Drucker was 'a true public health Renaissance man, driven by a deep commitment to fairness, and justice. He cared deeply about people — you can see it in his work on harm reduction, insisting we should not punish people for who they are and the decisions they make, but instead we should help them become healthier and more fulfilled.'
Ernest Mor Drucker was born on March 29, 1940, in Brooklyn. His father, Joseph, was a machinist for ITT. His wife, Beatrice (Strull) Drucker, managed the household.
Ernest was raised in the borough's Brighton Beach section, and graduated from Brooklyn Technical High School with plans to become an engineer, but he gravitated toward psychology as a major at City College of New York where he earned a bachelor's degree in 1962 followed by a doctorate.
At Montefiore/Einstein, where he was a disciple of Drs. H. Jack Geiger and Victor Sidel, two proponents of health care for the poor, he was the director of Public Health and Policy Research and the founding director of a 1,000-patient drug treatment program, where he served until 1990.
He would periodically reinvent himself professionally, shifting his focus to and from heroin addiction, public health, occupational safety, AIDS and alternatives to prison.
In addition to his son, Jesse, an investigative reporter for The New York Times, he is survived by his wife, Jeri (Rosner) Drucker, an artist; his brother, Alan Drucker; and two grandchildren.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

South Africa, Gates Foundation Pledge Funds to Sustain HIV Research After US Cuts
South Africa, Gates Foundation Pledge Funds to Sustain HIV Research After US Cuts

Bloomberg

time3 hours ago

  • Bloomberg

South Africa, Gates Foundation Pledge Funds to Sustain HIV Research After US Cuts

South Africa's government together with the Gates Foundation and Wellcome Trust have pledged 600 million rand ($33 million) in a step that could keep medical research projects including a key HIV vaccine trial running after the US slashed funding for the programs. The contribution, which sees the government's 400 million rand pledge over three years augmented by 100 million rand each from the foundations, will be available for defunded research programs including targeting diseases such as AIDS and tuberculosis, the South African Medical Research Council said in a statement on Monday.

Phase 1 Clinical Ttrial of HIV Vaccine Starts in Africa to Evaluate Immune Responses to Highly Networked HIV T-Cell Epitopes
Phase 1 Clinical Ttrial of HIV Vaccine Starts in Africa to Evaluate Immune Responses to Highly Networked HIV T-Cell Epitopes

Miami Herald

time7 hours ago

  • Miami Herald

Phase 1 Clinical Ttrial of HIV Vaccine Starts in Africa to Evaluate Immune Responses to Highly Networked HIV T-Cell Epitopes

Led by a team of African researchers, first doses of the novel T cell-inducing GRAdHIVNE1 vaccine candidate have been given. HARARE, ZIMBABWE, ROME, ITALY, NEW YORK, NY, AND CAMBRIDGE, MA / ACCESS Newswire / August 4, 2025 / The Mutala Trust, ReiThera Srl (ReiThera), the Ragon Institute of Mass General Brigham, MIT, and Harvard (the Ragon Institute), and IAVI are pleased to announce that the first doses of an investigational HIV vaccine candidate have been administered. The vaccine candidate, Gorilla Adenovirus Vectored HIV Networked Epitopes Vaccine (GRAdHIVNE1), was first administered on July 28, 2025, at the Mutala Trust clinical trial site in Harare, Zimbabwe. This effort is made possible by a global collaboration and a team of African principal investigators who will lead the clinical research in South Africa and Zimbabwe (listed below). Vaccine immunogenicity will also be assessed locally by a network of state-of-the-art African research institutes: Cape Town HVTN Immunology Laboratory in Cape Town, African Health Research Institute in Durban, and the National Institute for Communicable Diseases in Johannesburg, South Africa. This Phase 1, first-in-human clinical trial will enroll approximately 120 healthy adults aged 18-50 years, including 48 people living with HIV who are virally suppressed on antiretroviral therapy (ART). The trial is designed to assess the safety and immunogenicity of the vaccine candidate in people living with and without HIV. Participants will receive either one or two doses of the investigational vaccine or a placebo and will be monitored over a period of 19 months for safety and immune responses. This clinical trial, IAVI C114, is sponsored by IAVI. GRAdHIVNE1 has been made possible by a collaborative effort. ReiThera developed the GRAd viral vector platform and manufactured the vaccine candidate, while the Ragon Institute designed the immunogen using novel strategies to identify protective HIV epitopes and facilitate their targeting by T cells. This clinical program is funded by the Gates Foundation. The IAVI C114 clinical trial is taking place at three clinical trial sites: the Mutala Trust Clinical Trial Site, in Harare, Zimbabwe; the Desmond Tutu Health Foundation (DTHF), in Cape Town, South Africa; and the Africa Health Research Institute (AHRI), in Durban, South Africa. To determine the vaccine candidate's potential for relevance in sub-Saharan Africa, where disease burden is greatest, it is essential that the candidate be tested within communities affected by the epidemic. "This is a landmark moment for South Africa, Zimbabwe, and the continent. It shows the power of true partnership: IAVI's sponsorship, ReiThera's GRAd technology, the Ragon Institute's innovative immunogen built on decades of science, and African investigators co-leading every phase of the trial. We are edging closer to an HIV vaccine, made possible by global collaboration, with clinical trials conducted in Africa, for Africa, and for the world." said Dr. Tariro Makadzange, Clinical Trial Lead, Mutala Trust. "This trial represents the future of vaccine development, rooted in Africa, built through global partnerships, and designed for the communities most affected by HIV," said Dr. Vincent Muturi-Kioi, HIV Vaccines Product Development Team Lead at IAVI. The vaccine candidate is designed to engage the immune system to recognize and target critical structural regions of HIV using a clinically validated, potent, T cell-inducing GRAd vector. This approach will be evaluated to assess the ability of the vaccine candidate to direct strong CD8+ T cell immune responses towards these vulnerable viral regions. "We are thrilled to be moving insights from our long-term studies of spontaneous elite controllers of HIV toward the development of GRAdHIVNE1 and its testing in Africa. We are truly grateful to the network of global and African partners that have come together to make the IAVI C114 trial a reality," said Dr. Gaurav Gaiha, Associate Professor of Medicine at Harvard Medical School and Principal Investigator at the Ragon Institute of Mass General Brigham, MIT, and Harvard. Because CD8+ T cells induced by this vaccine hold promise for targeting HIV-infected cells, this clinical trial will also assess the safety and immune response in people living with HIV. These data will be used to assess the suitability of the vaccine candidate for the development of investigational HIV therapeutic and curative interventions. "We are enormously pleased with the launch of this Phase 1 trial representing the result of a successful global partnership," said Stefano Colloca, CEO and co-Founder of ReiThera. "This candidate HIV vaccine, built on our GRAd platform, holds great promise to trigger a strong CD8 response targeting vulnerable viral regions." Principal Investigators Leading Clinical Trial Sites: Tariro Makadzange, Mutala TrustTheodorah Rirhandzu Ndzhukule, DTHFLimakatso Lebina, AHRI About IAVI IAVI is a global nonprofit scientific organization that works to develop vaccines and antibodies to prevent HIV and other infectious diseases, with a focus on innovation and equitable access. IAVI is the sponsor of this trial. Read more at IAVI media contact Heather Teixeirahteixeira@ About Mutala Trust Mutala Trust is founding member of Africa Clinical Research Network (ACRN) and is a site based in Harare, Zimbabwe. It is known for conducting high-quality, ethically sound clinical trials addressing diseases that affect African communities. Mutala is the clinical lead site for the study. Mutala Trustmedia contact coms@ About ReiThera Srl. ReiThera Srl, an Italian CDMO specializing in technology and process development as well as GMP manufacturing of viral vectors for genetic vaccines and advanced therapies, is the developer and owner of the GRAd platform used for this HIV vaccine. ReiThera media contact communication@ About the Ragon Institute of Mass General Brigham, MIT, and Harvard The Ragon Institute of Mass General Brigham, MIT, and Harvard was established with a collaborative scientific mission among these institutions that brings scientists, clinicians and engineers together to harness the immune system to combat and cure human disease. They contributed to vaccine design. For more information, visit Ragon Institutemedia contact ragoncommunications@ SOURCE: IAVI

I've traveled the world to study brain health — here are 2 secrets to protecting against dementia
I've traveled the world to study brain health — here are 2 secrets to protecting against dementia

New York Post

time9 hours ago

  • New York Post

I've traveled the world to study brain health — here are 2 secrets to protecting against dementia

I'm going the extra mile for myelin. I travel the world to deliver neurological care in places with limited resources. Along the way, I have learned several important lessons about protecting brain health and preventing brain disease. My perspective was forever altered on one of my first trips to Uganda for the Department of Neurology at NYU Grossman School of Medicine. Advertisement I met a 14-year-old boy unable to move the left side of his body. Our medical team discovered the teen had undiagnosed and undetected HIV since birth. I was surprised to learn that HIV could be associated with stroke because it is an advanced feature of the virus that is infrequent in the US now. That knowledge changed my perceptions and attitudes towards brain health. Here is some wisdom from my visits to Uganda and Ghana, including two simple steps to halt and reverse brain damage. US vs the world The biggest difference in brain health challenges in the US and places like Ghana is simply access to care. Advertisement 3 Dr. Jaydeep Bhatt, director of the Division of Global Health for the Department of Neurology at NYU Grossman School of Medicine, reveals two major lessons for preventing brain disease. Most Americans can see their primary care physician to screen for risk factors leading to brain disease. Most Ghanaians do not have this level of access, so they are silently living with many risk factors. That leads to brain disease manifesting as a stroke or some other preventable brain disorder. A major, under-the-radar risk factor One risk factor for dementia that doesn't get a lot of attention is undetected hearing loss. Hearing loss is common with age. The problem is that good hearing is crucial for feeding the language centers, primarily located in the left hemisphere of the brain, with the proper information to produce language. Advertisement If hearing loss is not detected in a timely fashion, there might be improper funneling of information to this language area, increasing the risk of memory loss and dementia. Screening timetables Patients should be screened for brain-related conditions such as cognitive decline and stroke risk at least once a year. A preventative primary care physician will measure blood pressure, heart rate and cholesterol levels. Cardiovascular brain damage is tricky because it often has no immediate warning signs. High blood pressure is known in medicine as a 'silent killer' because you don't feel it as you're walking around. Advertisement 3 Bhatt visited Ghana and Uganda to study brain health. High blood pressure causes arteries and veins to narrow, which decreases nourishment and blood flow to the brain. This leads to changes detectable by modern MRI. Thankfully, these changes are in silent regions of the brain, so you will not have a disability. However, over time, memory loss, dementia and other harmful brain diseases can develop. High cholesterol, along with high blood pressure, contributes to these very same changes because it leads to blockages in important arteries that feed your brain with blood. Physical inactivity fuels high blood pressure, high cholesterol and other cardiovascular risk factors. Fortunately, brain damage from poor cardiovascular health can be stalled and even reversed. The traditional risk factors of high cholesterol, high blood pressure, diabetes and smoking are addressed by two behaviors — diet and exercise. Two ways to protect brain health When I traveled to Uganda and Ghana, one aspect of their diet that surprised me was their natural portion control. Advertisement The average Ghanaian and Ugandan meal is half or one-third the size of what we would expect of a meal in the US. American restaurants offer huge portions based on the idea that bigger is better, especially because it's more value for your money. But these larger meal sizes are just not meant for one person. So much of brain health is linked to the quality of your diet, including the amount you consume in one sitting. 3 The traditional risk factors of high cholesterol, high blood pressure, diabetes and smoking are addressed by two behaviors — diet and exercise. Advertisement Smaller portions and a lack of snacking between meals are inherent to cultures in Uganda and Ghana. Just by making more modest food choices at home, you can lessen your risk of brain disease. The right type of diet is not specific to one culture. Dietary approaches to stop hypertension or Mediterranean diets are rich in fruits and whole grains with low salt and less saturated fat. Exercise, which can occur in many different forms, is also essential to brain health. Advertisement No matter what neurological disease you may have heard of, the rate and severity of that disease are lessened with regular exercise. Exercise crosses cultures — I've seen it manifested in different ways as I've traveled the world and delivered neurological care. The other aspect of the culture in Uganda and Ghana that really struck me — in a good way — was the lack of alcohol and cigarette use. Drinking less alcohol and smoking less are well-established behaviors that lead to better brain health. The vast majority of both populations do not regularly partake in these activities. Advertisement Follow these recommendations to protect your brain as you age — and consult your physician with any concerns. Dr. Jaydeep Bhatt is the director of the Division of Global Health for the Department of Neurology at NYU Grossman School of Medicine.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store